Tumor Biology

, Volume 36, Issue 11, pp 8653–8660 | Cite as

RETRACTED ARTICLE: Regulation of MET-mediated proliferation of thyroid carcinoma cells by miR-449b

Research Article

Abstract

Thyroid carcinoma (TC) is a lethal cancer worldwide, whereas its carcinogenesis is not fully understood. Although growing evidence has demonstrated that dysregulation of microRNAs (miRNAs) contributes to the development of various cancers, the role of miRNAs in the pathogenesis of TC is poorly characterized. Here, we analyzed the levels of miR-449b in TC tissues and detected significantly lower miR-449b levels in TC tissues. Moreover, the low miR-449b levels were associated with poor survival. We then overexpressed miR-449b by miRNA mimic transfection and inhibited miR-449b by miRNA antisense transfection. Cell growth was analyzed by CCK-8 assay and MTT assay, and apoptosis and cell proliferation were analyzed by flow cytometry. Overexpression of miR-449b significantly inhibited cell growth, while depletion of miR-449b increased cell growth. Moreover, the effects of miR-449b on cell growth were through modulation of cell proliferation rather than through modulation of cell apoptosis. Targeted genes were predicted by a bioinformatics algorithm and confirmed by a dual luciferase reporter assay, showing that miR-449b binds to the 3′-UTR of MET (hepatocyte growth factor receptor) mRNA, to inhibit its expression in TC cells. MET levels were regulated by miR-449b in TT cells. Together, we show that reduced miR-449b levels in TT tissues may promote TC growth, through MET-mediated cell proliferation.

Keywords

Thyroid carcinoma (TC) MiR-449b MicroRNAs (miRNAs) Cancer cell proliferation Cancer cell apoptosis MET (hepatocyte growth factor receptor) 

Notes

Conflicts of interest

None

References

  1. 1.
    Zhang J, Wang Y, Li D, Jing S. Notch and TGF-beta/Smad3 pathways are involved in the interaction between cancer cells and cancer-associated fibroblasts in papillary thyroid carcinoma. Tumour Biol. 2014;35:379–85.CrossRefPubMedGoogle Scholar
  2. 2.
    Chen J, Liu C, Yin L, Zhang W. The tumor-promoting function of ECRG4 in papillary thyroid carcinoma and its related mechanism. Tumour Biol. 2015;36:1081–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Deng X, Wu B, Xiao K, Kang J, Xie J, Zhang X, et al. Mir-146b-5p promotes metastasis and induces epithelial-mesenchymal transition in thyroid cancer by targeting ZNRF3. Cell Physiol Biochem. 2015;35:71–82.CrossRefPubMedGoogle Scholar
  4. 4.
    Ulbrich C, Pietsch J, Grosse J, Wehland M, Schulz H, Saar K, et al. Differential gene regulation under altered gravity conditions in follicular thyroid cancer cells: relationship between the extracellular matrix and the cytoskeleton. Cell Physiol Biochem. 2011;28:185–98.CrossRefPubMedGoogle Scholar
  5. 5.
    Wang F, Wang P, Wang B, Fu ZJ, Yuan Y, Yan SL, et al. Association between TP53 Arg72Pro polymorphism and thyroid carcinoma risk. Tumour Biol. 2014;35:2723–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Wang H, Li YP, Chen JH, Yuan SF, Wang L, Zhang JL, et al. Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma. Tumour Biol. 2013;34:1635–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Wan L, Zhu L, Xu J, Lu B, Yang Y, Liu F, et al. MicroRNA-409-3p functions as a tumor suppressor in human lung adenocarcinoma by targeting c-Met. Cell Physiol Biochem. 2014;34:1273–90.CrossRefPubMedGoogle Scholar
  8. 8.
    Trusolino L, Bertotti A, Comoglio PM. Met signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11:834–48.CrossRefPubMedGoogle Scholar
  9. 9.
    Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis—correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met. Tumour Biol. 2013;34:2109–17.CrossRefPubMedGoogle Scholar
  10. 10.
    Liu H, Qian C, Shen Z. Anti-tumor activity of oridonin on SNU-5 subcutaneous xenograft model via regulation of c-Met pathway. Tumour Biol. 2014;35:9139–46.CrossRefPubMedGoogle Scholar
  11. 11.
    Huang J, Dong B, Zhang J, Kong W, Chen Y, Xue W, et al. miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma. Tumour Biol. 2014;35:5833–43.CrossRefPubMedGoogle Scholar
  12. 12.
    Samadi AK, Cohen SM, Mukerji R, Chaguturu V, Zhang X, Timmermann BN, et al. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation. Tumour Biol. 2012;33:1179–89.CrossRefPubMedGoogle Scholar
  13. 13.
    Li Y, Zhang S, Tang Z, Chen J, Kong W. Silencing of c-Met by RNA interference inhibits the survival, proliferation, and invasion of nasopharyngeal carcinoma cells. Tumour Biol. 2011;32:1217–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Grabellus F, Konik MJ, Worm K, Sheu SY, van de Nes JA, Bauer S, et al. MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions. Tumour Biol. 2010;31:157–63.CrossRefPubMedGoogle Scholar
  15. 15.
    Koo BS, Kim JM, Seo ST, Yoon YH, Kwon KR, Kim SH, et al. Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Ann Surg Oncol. 2014;21:2310–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Bentzien F, Zuzow M, Heald N, Gibson A, Shi Y, Goon L, et al. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid. 2013;23:1569–77.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Di Leva G, Croce CM. MiRNA profiling of cancer. Curr Opin Genet Dev. 2013;23:3–11.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Mei Q, Li F, Quan H, Liu Y, Xu H. Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014;105:755–62.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Wang F, Xiao W, Sun J, Han D, Zhu Y. MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. Tumour Biol. 2014;35:8653–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Liu G, Jiang C, Li D, Wang R, Wang W. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol. 2014;35:9801–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Bao J, Li D, Wang L, Wu J, Hu Y, Wang Z, et al. MicroRNA-449 and microRNA-34b/c function redundantly in murine testes by targeting E2F transcription factor-retinoblastoma protein (E2F-pRb) pathway. J Biol Chem. 2012;287:21686–98.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Yang X, Feng M, Jiang X, Wu Z, Li Z, Aau M, et al. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev. 2009;23:2388–93.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol. 2014;32:353–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Fang Y, Gu X, Li Z, Xiang J, Chen Z. miR-449b inhibits the proliferation of SW1116 colon cancer stem cells through downregulation of CCND1 and E2F3 expression. Oncol Rep. 2013;30:399–406.PubMedGoogle Scholar
  26. 26.
    Dzikiewicz-Krawczyk A, Macieja A, Maly E, Januszkiewicz-Lewandowska D, Mosor M, Fichna M, et al. Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding. J Hematol Oncol. 2014;7:43.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Chung TK, Lau TS, Cheung TH, Yim SF, Lo KW, Siu NS, et al. Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer. 2012;130:1036–45.CrossRefPubMedGoogle Scholar
  28. 28.
    Ostling P, Leivonen SK, Aakula A, Kohonen P, Makela R, Hagman Z, et al. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res. 2011;71:1956–67.CrossRefPubMedGoogle Scholar
  29. 29.
    Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, et al. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res. 1997;57:5309–19.PubMedGoogle Scholar
  30. 30.
    Coronnello C, Benos PV. ComiR: combinatorial microRNA target prediction tool. Nucleic Acids Res. 2013;41:W159–164.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of General Surgery, The Tenth People’s HospitalTongji UniversityShanghaiChina

Personalised recommendations